Company Overview of F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd. provides in-vitro diagnostics and drugs for cancer and transplantation. The company specializes in medicines for oncology, virology, inflammation, metabolism, CNS, clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. Its products include cancer treatments, such as Avastin, Herceptin, and MabThera that are also effective in the treatment of rheumatoid arthritis, anemia, and osteoporosis. The company also researches, develops, and produces molecular diagnostic reagents, test systems, and test kits. In addition, it provides automated instruments, software, consumables, and IT solutions used in in-vitro diagnostic...
Founded in 1989
Key Executives for F. Hoffmann-La Roche Ltd
Compensation as of Fiscal Year 2013.
F. Hoffmann-La Roche Ltd Key Developments
F. Hoffmann-La Roche Ltd Receives CE Mark for New Version of HIV Diagnostic Test
Feb 28 14
F. Hoffmann-La Roche Ltd. has announced that its dual-target HIV-1 qualitative test, v2.0, has received CE Mark certifications, allowing it to be sold for clinical use in the European Union and those countries accepting CE Marked products. The test simultaneously amplifies and detects two separate regions of the HIV-1 genome, which are not subject to selective drug pressure. This dual target design allows for more reliable results to confidently and effectively diagnose HIV-1 infection. The new dual-target HIV-1 qualitative test, v2.0 works with both plasma and dried blood spot (DBS) collection cards to facilitate PCR testing, and more importantly make sample collection and transportation easy, even from the smallest infant in the most rural area. The DBS collection card and the need for more sensitive and accurate information to diagnose babies early in their life and patients across many African countries is instrumental to facilitate healthcare required for the region. The HIV-1 dual target qualitative test and DBS cards eliminates need for refrigeration, drastically reduces the volume of blood to be stored or transported, and the stress for the mother and the child is dramatically improved. The COBAS AmpliPrep/COBAS TaqMan HIV-1 Qualitative Test, version 2.0 is an in vitro diagnostic, total nucleic acid amplification test for the qualitative detection of Human Immunodeficiency Virus Type 1 (HIV-1) DNA and RNA (or total nucleic acid, TNA) in human plasma or dried blood spots using the COBAS AmpliPrep Instrument for automated specimen processing and the COBAS TaqMan Analyzer or COBAS TaqMan 48 Analyzer for automated amplification and detection.
F. Hoffmann-La Roche Ltd Announces Earnings Results for the Year 2013
Feb 13 14
F. Hoffmann-La Roche Ltd. announced earnings results for the year 2013. The company has reported that net income for 2013 was CHF 11.37 billion, or CHF 14.27 per share, compared to CHF 9.66 billion, or CHF 13.49 per share, for 2012. Group sales for 2013 were CHF 46.78 billion, compared to CHF 45.50 billion for 2012. Core operating profit for 2013 was CHF 17.90 billion, compared to CHF 17.16 billion for 2012.
PDL BioPharma, Inc. Announces Settlement Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd
Feb 3 14
PDL BioPharma, Inc. announced that it has entered into an agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. which resolves all outstanding legal disputes between the parties, including its Nevada litigation with Genentech and Roche and its arbitration proceedings with Genentech related to the audit of royalties on sales. Under the terms of the agreement, effective retroactively to August 15, 2013, Genentech will pay a fixed royalty rate of 2.125% on worldwide sales of Avastin, Herceptin, Lucentis Xolair, Kadcyla and Perjeta, as compared to the previous tiered royalty rate in the U.S and the fixed rate on all ex-U.S based manufactured and sold licensed products. Pursuant to the agreement, Genentech and Roche confirm that Avastin, Herceptin, Lucentis, Xolair and Perjeta are licensed products as defined in the relevant license agreements between the parties, and further agree that Kadcyla is a licensed product. Genentech will pay these royalties on all worldwide sales of Avastin, Herceptin, Xolair, Perjeta and Kadcyla occurring on or before December 31, 2015. With respect to Lucentis, Genentech will owe no royalties on U.S. sales occurring after June 30, 2013, and will pay a royalty of 2.125% on all ex-U.S. sales occurring on or before December 28, 2014. Pursuant to a separate agreement, Roche Glycart agreed that Gazyva is a licensed product. The royalty term and royalty rate for Gazyva remain unchanged from the existing license agreement pertaining thereto. The agreement precludes Genentech and Roche from challenging the validity of PDL's Queen patents, including its supplementary protection certificates in Europe, from contesting their obligation to pay royalties, from contesting patent coverage for Avastin, Herceptin, Lucentis, Xolair, Perjeta, Kadcyla and Gazyva and from assisting any third party in challenging PDL's Queen patents and SPCs. The agreement further outlines the conduct of any audits initiated by PDL of the books and records of Genentech in an effort to ensure a full and fair audit procedure. Finally, the agreement clarifies that the sales amounts from which the royalties are calculated do not include certain taxes and discounts. PDL expects to recognize royalty revenue on the licensed products until the first quarter of 2016.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|